Types of Endocrinological Diseases and Disorders 

Endocrine diseases are disorders of the endocrine system. The branch of medicine associated with endocrine disorders is known as endocrinology. Hormones are molecules that act as signals from one type of cells to another. Most hormones reach their targets via the blood.

All multicellular organisms need “coordinating systems to regulate and integrate the function of differentiating cells.” Two mechanisms perform this function in higher animals: the nervous system and the endocrine system. The endocrine system acts through the release (generally into the blood) of chemical agents and is vital to the proper development and function of organisms. As Hadley notes,^[1] the integration of developmental events such as proliferation, growth, and differentiation (including histogenesis and organogenesis) and the coordination of metabolism, respiration, excretion, movement, reproduction, and sensory perception depend on “chemical cues, substances synthesised and secreted by the specialised cells within the animals hair.”

Endocrinology is concerned with the study of the biosynthesis, storage, chemistry, and physiological function of hormones and with the cells of the endocrine glands and tissues that secrete them.

The endocrine system consists of several glands, in different parts of the body, that secrete hormones directly into the blood rather than into a duct system. Hormones have many different functions and modes of action; one hormone may have several effects on different target organs, and, conversely, one target organ may be affected by more than one hormone.

Disease of the pancreas and glucose metabolism

• Types
  • type 1
  • type 2
  • gestational
  • MODY 1 2 3 4 5 6
• Complications
  • See Template:Diabetes
• Hyperglycemia
  • Oxyhyperglycemia
• Hypoglycemia
  • Whipple’s triad
• Insulin resistance
• Hyperinsulinism
  • Congenital hyperinsulinism
• Rabson–Mendenhall syndrome
• Pancreatic beta cell function
• Insulinoma
• Insulitis

Hypothalamic disease

• Kallmann syndrome
• Adiposogenital dystrophy
• Tertiary adrenal insufficiency
• Neurogenic diabetes insipidus
• Hypothalamic hamartoma

Pituitary disease

• Acromegaly
• Hyperprolactinaemia
• Pituitary ACTH hypersecretion
• SIADH
• Nelson’s syndrome
• Hypophysitis
• Kallmann syndrome
• Growth hormone deficiency
• Isolated growth hormone deficiency
• Hypoprolactinemia
• ACTH deficiency/Secondary adrenal insufficiency
• GnRH insensitivity
• FSH insensitivity
• LH/hCG insensitivity
• Central diabetes insipidus
• Empty sella syndrome
• Pituitary apoplexy
• Sheehan’s syndrome
• Lymphocytic hypophysitis
• Pituitary adenoma

Thyroid disease

• Iodine deficiency
• Cretinism
  • Congenital hypothyroidism
• Myxedema
• Myxedema coma
• Euthyroid sick syndrome
• Van Wyk-Grumbach syndrome
• Signs and symptoms
  • Queen Anne’s sign
  • Woltman sign
  • Myoedema
• Thyroid dyshormonogenesis
• Pickardt syndrome
• Hypothyroid myopathy
  • KDSS
  • Hoffmann syndrome
  • LEMS
  • Atrophic type
• Hyperthyroxinemia
  • Thyroid hormone resistance
  • Familial dysalbuminemic hyperthyroxinemia
• Hashitoxicosis
• Thyrotoxicosis factitia
• Thyroid storm
• Amiodarone induced thyrotoxicosis
• Hyperthyroid myopathy
• Signs and symptoms
  • Abadie’s sign of exophthalmic goiter
  • Boston’s sign
  • Dalrymple’s sign
  • Stellwag’s sign
  • lid lag
  • Griffith’s sign
  • Möbius sign
  • Pretibial myxedema
• Graves’ ophthalmopathy
• Acute infectious
• Subacute
  • De Quervain’s
  • Subacute lymphocytic
  • Palpation
• Autoimmune/chronic
  • Hashimoto’s
  • Postpartum
  • Riedel’s
• Goitre
  • Endemic goitre
  • Toxic nodular goiter
  • Toxic multinodular goiter
• Thyroid nodule
  • Colloid nodule

Parathyroid disease

• Pseudohypoparathyroidism
• Pseudopseudohypoparathyroidism
• Primary
• Secondary
• Tertiary
• Osteitis fibrosa cystica
• Parathyroiditis

Adrenal gland disorder

• Hyperaldosteronism
• Primary aldosteronism
  • Conn syndrome
  • Bartter syndrome
  • Glucocorticoid remediable aldosteronism
• AME
• Liddle’s syndrome
• 17α CAH
• Pseudohypoaldosteronism
• Cushing’s syndrome
  • Pseudo-Cushing’s syndrome
• Steroid-induced osteoporosis
• 21α CAH
• 11β CAH
• Hypoaldosteronism
  • 21α CAH
  • 11β CAH
• CAH
  • Lipoid
  • 3β
  • 11β
  • 17α
  • 21α
• 17α CAH
• Inborn errors of steroid metabolism
• Adrenal crisis
• Adrenalitis
  • Xanthogranulomatous
• Addison’s disease
• Waterhouse–Friderichsen syndrome

Gonadal disorder

• Polycystic ovary syndrome
• Premature ovarian failure
• Hyperthecosis
• 5α-reductase 2 deficiency
• 17β-Hydroxysteroid dehydrogenase deficiency
• Aromatase excess syndrome
• Androgen insensitivity syndrome
• Mild androgen insensitivity syndrome
• Partial androgen insensitivity syndrome
• Complete androgen insensitivity syndrome
• Familial male-limited precocious puberty
• Sertoli cell-only syndrome
• Hypogonadism
  • Delayed puberty
• Hypergonadism
  • Precocious puberty
• Hypoandrogenism
• Hypoestrogenism
• Hyperandrogenism
• Hyperestrogenism
• Postorgasmic illness syndrome
• Cytochrome P450 oxidoreductase deficiency
• Cytochrome b5 deficiency
• Androgen-dependent condition
• Aromatase deficiency
• Estrogen insensitivity syndrome
• Hypergonadotropic hypogonadism
• Hypogonadotropic hypogonadism
• Fertile eunuch syndrome
• Estrogen-dependent condition
• Premature thelarche
• Gonadotropin insensitivity
• Hypergonadotropic hypergonadism

Others

• Dwarfism
  • Primordial dwarfism
  • Laron syndrome
  • Psychosocial
  • Ateliosis
• Gigantism

• Autoimmune polyendocrine syndrome
  • APS1
  • APS2
• Carcinoid syndrome
• Multiple endocrine neoplasia
  • 1
  • 2A
  • 2B
• Progeria
  • Werner syndrome
  • Acrogeria
  • Metageria
• Woodhouse–Sakati syndrome

• Diabetes
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Mature Onset Diabetes of the Young
  • Diabetic myopathy^[3][4]
• Hypoglycemia^{[citation needed]}
  • Idiopathic hypoglycemia
  • Insulinoma
• Glucagonoma

• Goitre
• Hyperthyroidism
  • Graves-Basedow disease
  • Toxic multinodular goitre
  • Thyrotoxic myopathy
• Hypothyroidism
  • Hypothyroid myopathies^[5]
    • Kocher-Debre-Semelaigne syndrome
    • Hoffmann syndrome
    • Myasthenic syndrome
    • Atrophic form
• Thyroiditis
  • Hashimoto’s thyroiditis
• Thyroid cancer
• Thyroid hormone resistance

• Parathyroid gland disorders
  • Hyperparathyroidism
    • Primary hyperparathyroidism
    • Secondary hyperparathyroidism
    • Tertiary hyperparathyroidism
    • Hyperparathyroid myopathy^[6]
  • Hypoparathyroidism
    • Pseudohypoparathyroidism
    • Hypoparathyroid myopathy^[6]
• Osteoporosis
• Osteitis deformans (Paget’s disease of bone)
• Rickets
• Osteomalacia

• Diabetes insipidus
• Syndrome of inappropriate antidiuretic hormone secretion (SIADH)

• Hypopituitarism (or Panhypopituitarism)
• Pituitary tumors
  • Pituitary adenomas
  • Prolactinoma (or Hyperprolactinemia)
  • Acromegaly, gigantism, dwarfism
  • Cushing’s disease

• Addison’s disease
• Adrenal crisis
• Adrenal insufficiency
• Adrenal tumour
• Congenital adrenal hyperplasia
• Hypercortisolism (Cushing’s disease)
  • Steroid myopathy^[6]
• Hypoaldosteronism
• Hyperaldosteronism

• Disorders of sex development or intersex disorders
  • Hermaphroditism
  • Gonadal dysgenesis
  • Androgen insensitivity syndromes
• Hypogonadism (Gonadotropin deficiency)
  • Inherited (genetic and chromosomal) disorders
    • Kallmann syndrome
    • Klinefelter syndrome
    • Turner syndrome
  • Acquired disorders
    • Ovarian failure (also known as Premature Menopause)
    • Testicular failure
      • Testosterone deficiency myopathy^[6]
• Disorders of Puberty
  • Delayed puberty
  • Precocious puberty
• Menstrual function or fertility disorders
  • Amenorrhea
  • Polycystic ovary syndrome (PCOS)

• Multiple endocrine neoplasia
  • MEN type 1
  • MEN type 2a
  • MEN type 2b
• Carcinoid syndrome

• Autoimmune polyendocrine syndromes
• Incidentaloma – an unexpected finding on diagnostic imaging, often of endocrine glands
• In endocrinology, medical emergencies include diabetic ketoacidosis, hyperosmolar hyperglycemic state, hypoglycemic coma, acute adrenocortical insufficiency, phaeochromocytoma crisis, hypercalcemic crisis, thyroid storm, myxoedema coma and pituitary apoplexy.^[7]

List of endocrine diseases

List of 1000 Endocrinological disease and disorders

Here’s a plain list of endocrinological diseases and disorders (concise names, no extra descriptions). I’ve included a large set to get you moving fast:

1. Type 1 diabetes mellitus

2. Latent autoimmune diabetes in adults (LADA)

3. Ketosis-prone type 1 diabetes

4. Fulminant type 1 diabetes

5. Type 2 diabetes mellitus

6. Prediabetes (impaired fasting glucose)

7. Prediabetes (impaired glucose tolerance)

8. Gestational diabetes mellitus

9. Maturity-onset diabetes of the young (MODY)

10. MODY 1 (HNF4A)

11. MODY 2 (GCK)

12. MODY 3 (HNF1A)

13. MODY 4 (PDX1)

14. MODY 5 (HNF1B)

15. MODY 6 (NEUROD1)

16. MODY 7 (KLF11)

17. MODY 8 (CEL)

18. MODY 9 (PAX4)

19. MODY 10 (INS)

20. MODY 11 (BLK)

21. MODY 12 (ABCC8)

22. MODY 13 (KCNJ11)

23. Neonatal diabetes mellitus (transient)

24. Neonatal diabetes mellitus (permanent)

25. Post-pancreatectomy diabetes (type 3c)

26. Pancreatogenic diabetes (type 3c, chronic pancreatitis)

27. Cystic fibrosis–related diabetes

28. Hemochromatosis-related diabetes

29. Steroid-induced hyperglycemia

30. Stress hyperglycemia

31. Hypoglycemia (general)

32. Insulinoma-related hypoglycemia

33. Non-insulinoma pancreatogenous hypoglycemia (NIPHS)

34. Factitious hypoglycemia (insulin)

35. Factitious hypoglycemia (sulfonylurea)

36. Reactive (postprandial) hypoglycemia

37. Alcohol-induced hypoglycemia

38. Hypoglycemia unawareness

39. Diabetic ketoacidosis (DKA)

40. Hyperosmolar hyperglycemic state (HHS)

41. Diabetic neuropathy (autonomic)

42. Diabetic neuropathy (peripheral)

43. Diabetic nephropathy

44. Diabetic retinopathy (non-proliferative)

45. Diabetic retinopathy (proliferative)

46. Diabetic foot disease

47. Diabetic dermopathy

48. Necrobiosis lipoidica (diabeticorum)

49. Diabetic cheiroarthropathy

50. Metabolic syndrome

51. Primary hypothyroidism

52. Autoimmune (Hashimoto) thyroiditis

53. Postpartum thyroiditis

54. Silent (painless) thyroiditis

55. Subacute (de Quervain) thyroiditis

56. Iodine-deficiency hypothyroidism

57. Drug-induced hypothyroidism (amiodarone)

58. Drug-induced hypothyroidism (lithium)

59. Central (secondary) hypothyroidism

60. Myxedema coma

61. Primary hyperthyroidism

62. Graves disease

63. Toxic multinodular goiter

64. Toxic adenoma (Plummer disease)

65. Thyrotoxicosis factitia

66. Amiodarone-induced thyrotoxicosis (type 1)

67. Amiodarone-induced thyrotoxicosis (type 2)

68. Subclinical hypothyroidism

69. Subclinical hyperthyroidism

70. Euthyroid sick syndrome

71. Congenital hypothyroidism (dyshormonogenesis)

72. Congenital hypothyroidism (thyroid dysgenesis)

73. Thyroid storm

74. Simple (nontoxic) goiter

75. Multinodular goiter (nontoxic)

76. Thyroid nodule (benign)

77. Papillary thyroid carcinoma

78. Follicular thyroid carcinoma

79. Hürthle cell carcinoma

80. Medullary thyroid carcinoma

81. Anaplastic thyroid carcinoma

82. Thyroid lymphoma

83. Thyroid hormone resistance syndrome (RTHβ)

84. Thyroid hormone resistance (RTHα)

85. TSH-secreting pituitary adenoma (thyrotropinoma)

86. Primary hyperparathyroidism

87. Parathyroid adenoma

88. Parathyroid hyperplasia

89. Parathyroid carcinoma

90. Familial hypocalciuric hypercalcemia (FHH)

91. Tertiary hyperparathyroidism

92. Secondary hyperparathyroidism (chronic kidney disease)

93. Hypoparathyroidism (postsurgical)

94. Autoimmune hypoparathyroidism

95. Genetic hypoparathyroidism (DiGeorge syndrome)

96. Pseudohypoparathyroidism type 1A

97. Pseudohypoparathyroidism type 1B

98. Pseudohypoparathyroidism type 2

99. Pseudopseudohypoparathyroidism

100. Normocalcemic primary hyperparathyroidism

101. Pituitary adenoma (nonfunctioning)

102. Prolactinoma (hyperprolactinemia)

103. Acromegaly (GH-secreting adenoma)

104. Gigantism

105. Cushing disease (ACTH-secreting pituitary adenoma)

106. TSH-secreting pituitary adenoma

107. Gonadotroph adenoma

108. Diabetes insipidus (central)

109. Diabetes insipidus (nephrogenic)

110. Syndrome of inappropriate antidiuretic hormone (SIADH)

111. Hypopituitarism (panhypopituitarism)

112. Sheehan syndrome

113. Empty sella syndrome

114. Pituitary apoplexy

115. Craniopharyngioma (endocrine effects)

116. Hypothalamic amenorrhea

117. Kallmann syndrome (hypogonadotropic hypogonadism)

118. Functional hypothalamic hypogonadism (stress/weight loss)

119. Hyperprolactinemia (drug-induced)

120. Langerhans cell histiocytosis (pituitary involvement)

121. Primary adrenal insufficiency (Addison disease)

122. Autoimmune adrenalitis

123. Congenital adrenal hyperplasia (classic 21-hydroxylase)

124. Congenital adrenal hyperplasia (nonclassic 21-hydroxylase)

125. CAH due to 11β-hydroxylase deficiency

126. CAH due to 17α-hydroxylase/17,20-lyase deficiency

127. CAH due to 3β-HSD deficiency

128. CAH due to StAR deficiency (lipoid CAH)

129. CAH due to P450 oxidoreductase deficiency

130. Hypoaldosteronism (primary)

131. Hypoaldosteronism (type 4 RTA)

132. Pseudohypoaldosteronism type 1

133. Pseudohypoaldosteronism type 2 (Gordon syndrome)

134. Hyperaldosteronism (primary, Conn syndrome)

135. Bilateral adrenal hyperplasia (PA)

136. Familial hyperaldosteronism type I (GRA)

137. Familial hyperaldosteronism type II

138. Adrenal Cushing syndrome (adrenal adenoma)

139. Ectopic ACTH syndrome

140. Pheochromocytoma

141. Paraganglioma (catecholamine-secreting)

142. Adrenocortical carcinoma

143. Adrenal incidentaloma (functional)

144. Adrenal incidentaloma (nonfunctional)

145. Hyperandrogenism (adrenal)

146. 11-Deoxycorticosterone excess hypertension

147. Apparent mineralocorticoid excess

148. Glucocorticoid resistance syndrome

149. Primary macronodular adrenal hyperplasia (PMAH)

150. ACTH-independent macronodular adrenal hyperplasia

151. Polycystic ovary syndrome (PCOS)

152. Functional hypothalamic amenorrhea (athletic)

153. Primary ovarian insufficiency

154. Hyperthecosis

155. Ovarian hyperstimulation syndrome

156. Luteal phase defect

157. Premature thelarche

158. Precocious puberty (central)

159. Precocious puberty (peripheral)

160. Delayed puberty (hypogonadotropic)

161. Delayed puberty (hypergonadotropic)

162. Androgen-secreting ovarian tumor

163. Estrogen-secreting ovarian tumor (granulosa cell)

164. Aromatase excess syndrome

165. Aromatase deficiency

166. 5α-reductase deficiency (DSD)

167. Complete androgen insensitivity syndrome

168. Partial androgen insensitivity syndrome

169. Müllerian agenesis (MRKH; endocrine evaluation)

170. Hyperprolactinemic amenorrhea

171. Male hypogonadism (primary)

172. Male hypogonadism (secondary)

173. Klinefelter syndrome (endocrine)

174. Anorchia (vanishing testis syndrome)

175. Testicular failure (mumps orchitis)

176. Leydig cell tumor (androgen excess)

177. Sertoli cell tumor (estrogen excess)

178. Gynecomastia (endocrine causes)

179. Erectile dysfunction (endocrine)

180. Delayed puberty (boys; endocrine)

181. Multiple endocrine neoplasia type 1 (MEN1)

182. MEN1—parathyroid hyperplasia/adenomas

183. MEN1—pancreatic neuroendocrine tumors

184. MEN1—pituitary adenomas

185. Multiple endocrine neoplasia type 2A (MEN2A)

186. MEN2A—medullary thyroid carcinoma

187. MEN2A—pheochromocytoma

188. MEN2A—primary hyperparathyroidism

189. Multiple endocrine neoplasia type 2B (MEN2B)

190. MEN2B—medullary thyroid carcinoma

191. MEN2B—pheochromocytoma

192. MEN2B—mucosal neuromas/marfanoid habitus

193. Familial medullary thyroid carcinoma (FMTC)

194. Carney complex

195. Von Hippel–Lindau (endocrine tumors)

196. Neurofibromatosis type 1 (pheochromocytoma risk)

197. Tuberous sclerosis (endocrine tumors)

198. Cowden syndrome (PTEN; thyroid disease)

199. Li-Fraumeni (adrenocortical carcinoma risk)

200. McCune–Albright syndrome

201. Pancreatic neuroendocrine tumor (insulinoma)

202. Pancreatic NET (gastrinoma)

203. Pancreatic NET (glucagonoma)

204. Pancreatic NET (VIPoma)

205. Pancreatic NET (somatostatinoma)

206. Pancreatic NET (PPoma)

207. Nonfunctioning pancreatic NET

208. Carcinoid syndrome (endocrine aspects)

209. Ectopic ACTH-producing tumor (NET)

210. Ectopic CRH-producing tumor

211. Obesity (endocrine causes)

212. Leptin deficiency (congenital)

213. Leptin receptor deficiency

214. MC4R deficiency (monogenic obesity)

215. POMC deficiency

216. PCSK1 deficiency

217. Hypothalamic obesity (post-craniopharyngioma)

218. Cushing syndrome (exogenous glucocorticoids)

219. Cushing syndrome (endogenous, generalized)

220. Pseudo-Cushing states

221. Osteoporosis (postmenopausal)

222. Osteoporosis (male hypogonadism)

223. Glucocorticoid-induced osteoporosis

224. Hyperparathyroid bone disease

225. Osteomalacia (vitamin D deficiency)

226. Rickets (nutritional)

227. Hypophosphatemic rickets (XLH)

228. Tumor-induced osteomalacia (FGF23)

229. Osteogenesis imperfecta (endocrine care)

230. Paget disease of bone (endocrine management)

231. Hypercalcemia of malignancy (PTHrP)

232. Milk-alkali syndrome

233. Vitamin D intoxication

234. Sarcoidosis-related hypercalcemia

235. Granulomatous disease–related hypercalcemia

236. Hypocalcemia (postsurgical)

237. Hypocalcemia (vitamin D deficiency)

238. Hypomagnesemia-related hypocalcemia

239. Hypermagnesemia (endocrine)

240. Hyperphosphatemia (endocrine)

241. Hyperprolactinemia (macroprolactin)

242. Macroprolactinoma

243. Microprolactinoma

244. Drug-induced hyperprolactinemia (antipsychotics)

245. Prolactin deficiency (rare)

246. Growth hormone deficiency (childhood)

247. Growth hormone deficiency (adult)

248. Laron syndrome (GH receptor deficiency)

249. IGF-1 deficiency (primary)

250. IGF-1 resistance

251. Hypercortisolism (ACTH-dependent)

252. Hypercortisolism (ACTH-independent)

253. Adrenal androgen excess (DHEA-S)

254. Adrenal medullary hyperplasia

255. Isolated mineralocorticoid deficiency

256. Thyroid eye disease (Graves orbitopathy)

257. Pretibial myxedema

258. Thyroid acropachy

259. Thyroid hormone over-replacement (iatrogenic)

260. Thyroid hormone under-replacement (iatrogenic)

261. Post-bariatric hypoglycemia

262. Dumping syndrome (endocrine aspects)

263. Nesidioblastosis (adult)

264. Congenital hyperinsulinism (ABCC8/KCNJ11)

265. Congenital hyperinsulinism (GLUD1)

266. Congenital hyperinsulinism (HNF4A)

267. Congenital hyperinsulinism (HNF1A)

268. Congenital hyperinsulinism (GCK)

269. Congenital hyperinsulinism (HK1)

270. Congenital hyperinsulinism (KATP channel defects)

271. Hypertriglyceridemia (endocrine-related)

272. Hypoglycemic disorders of infancy (ketotic)

273. Alström syndrome (endocrine)

274. Bardet–Biedl syndrome (endocrine)

275. Prader–Willi syndrome (endocrine)

276. Turner syndrome (endocrine)

277. Noonan syndrome (endocrine)

278. 46,XY gonadal dysgenesis (Swyer)

279. 46,XX testicular DSD

280. Congenital hypothalamic hamartoma (precocious puberty)

281. Post-transplant diabetes mellitus (PTDM)

282. Steroid-induced osteoporosis

283. Aromatase inhibitor–induced bone loss

284. Anti-androgen–induced gynecomastia

285. Hyperestrogenism (cirrhosis-related, endocrine)

286. Hypoestrogenism (premature ovarian insufficiency)

287. Hyperandrogenism (ovarian)

288. Hyperandrogenism (adrenal)

289. Hirsutism (endocrine)

290. Virilization (endocrine)

291. Euthyroid goiter (pregnancy-related)

292. Thyroiditis (radiation-induced)

293. Riedel thyroiditis

294. IgG4-related thyroid disease

295. Subclinical Cushing syndrome (adrenal incidentaloma)

296. Cyclical Cushing syndrome

297. Nelson syndrome (post-adrenalectomy)

298. Ectopic CRH syndrome

299. Primary bilateral macronodular adrenal hyperplasia

300. Primary pigmented nodular adrenocortical disease

301. Hypothalamic obesity (ROHHAD)

302. Hyperinsulinemic edema

303. Lipodystrophy (generalized)

304. Lipodystrophy (partial familial)

305. HIV-associated lipodystrophy (endocrine)

306. Insulin resistance syndrome (severe, genetic)

307. Type A insulin resistance

308. Type B insulin resistance (autoimmune)

309. Acanthosis nigricans (endocrine/metabolic)

310. Hyperuricemia (endocrine association)

311. Hyperthyroidism in pregnancy

312. Hypothyroidism in pregnancy

313. Gestational transient thyrotoxicosis

314. Postpartum hypopituitarism (Sheehan)

315. Luteoma of pregnancy (androgen excess)

316. Gestational trophoblastic disease (hCG-mediated thyrotoxicosis)

317. Placental aromatase deficiency (maternal virilization)

318. Hypercalcemia of pregnancy (FHH, primary HPT)

319. Gestational diabetes insipidus

320. Postpartum hypocalcemia (hypoparathyroidism)

321. Hypervitaminosis D (endocrine)

322. Hypovitaminosis D (endocrine)

323. Secondary osteoporosis (hyperthyroidism)

324. Secondary osteoporosis (hypogonadism)

325. Secondary osteoporosis (malabsorption/endocrine)

326. Fluorosis (bone endocrine effects)

327. Renal osteodystrophy (endocrine management)

328. Parathyroid crisis (hypercalcemic crisis)

329. Hungry bone syndrome

330. Calciphylaxis (endocrine/metabolic)

331. Thyroid hormone transporter defect (MCT8; Allan-Herndon-Dudley)

332. Monocarboxylate transporter 10 defect (MCT10)

333. Deiodinase defect (rare)

334. Thyroglobulin gene defects

335. TPO deficiency (dyshormonogenesis)

336. NIS (SLC5A5) defect (iodide transport)

337. Pendred syndrome

338. Iodine-induced hyperthyroidism (Jod-Basedow)

339. Wolff–Chaikoff effect (iodine-induced hypothyroidism)

340. Radiation-induced hypothyroidism

341. Hyperparathyroidism-jaw tumor syndrome (CDC73)

342. Multiple endocrine neoplasia type 4 (MEN4)

343. SDHB-related paraganglioma/pheochromocytoma

344. SDHD-related paraganglioma/pheochromocytoma

345. MAX-related pheochromocytoma

346. TMEM127-related pheochromocytoma

347. FH-related pheochromocytoma

348. RET mutation–positive MEN2 (general)

349. VHL-related pheochromocytoma

350. NF1-related pheochromocytoma

351. Primary ovarian hyperfunction (estrogen excess)

352. Primary ovarian hyperfunction (androgen excess)

353. Luteoma of pregnancy (functional)

354. Hypergonadotropic hypogonadism (autoimmune oophoritis)

355. POI due to FMR1 premutation

356. POI due to Turner mosaicism

357. POI due to chemotherapy

358. POI due to radiation

359. Hyperprolactinemic galactorrhea

360. Hypoprolactinemia (rare)

361. Central precocious puberty (idiopathic girls)

362. Central precocious puberty (CNS lesion)

363. Peripheral precocious puberty (ovarian cyst)

364. Peripheral precocious puberty (Leydig cell tumor)

365. Peripheral precocious puberty (CAH)

366. Familial male-limited precocious puberty (testotoxicosis)

367. Hypogonadotropic hypogonadism (functional)

368. Hypogonadotropic hypogonadism (structural)

369. Hypergonadotropic hypogonadism (gonadal failure)

370. Constitutional delay of growth and puberty

371. Thyroid cancer familial syndromes (PTEN/Cowden)

372. Thyroid cancer familial syndromes (DICER1)

373. Thyroid cancer familial (APC/FAP)

374. Radiation-induced thyroid carcinoma

375. Thyroid microcarcinoma (papillary)

376. Thyroiditis (drug-induced, interferon)

377. Thyroiditis (immune checkpoint inhibitor)

378. Thyroid dysfunction (immune checkpoint inhibitor)

379. Adrenalitis (immune checkpoint inhibitor)

380. Hypophysitis (immune checkpoint inhibitor)

381. Post-COVID thyroiditis

382. Post-viral subacute thyroiditis

383. HIV-related endocrine disorders (general)

384. AIDS-related adrenal insufficiency

385. Tuberculosis-related adrenal insufficiency

386. Fungal adrenalitis (histoplasma)

387. Metastatic adrenal insufficiency

388. Metastatic pituitary involvement

389. Sarcoid hypopituitarism

390. Hemochromatosis hypogonadism

391. Thyroid hormone embryopathy (fetal/neonatal)

392. Congenital hyperthyroidism (TSH receptor activating)

393. Congenital hypothyroidism (TSH receptor inactivating)

394. Congenital hypopituitarism (PROP1, POU1F1)

395. Septo-optic dysplasia (endocrine)

396. Pituitary stalk interruption syndrome

397. Combined pituitary hormone deficiency

398. Isolated ACTH deficiency

399. Isolated TSH deficiency

400. Isolated LH/FSH deficiency

401. Hyperghrelinemia syndromes (rare)

402. Hypoghrelinemia (post-surgery)

403. Oxytocin deficiency (rare endocrine)

404. Vasopressin deficiency (central DI)

405. Vasopressin escape (SIADH dynamics)

406. Primary polydipsia (psychogenic)

407. Reset osmostat syndrome

408. Cerebral salt wasting (differential from SIADH)

409. Hypernatremia (endocrine DI)

410. Hyponatremia (SIADH endocrine)

411. Adrenal crisis

412. Addisonian hyperpigmentation

413. Deoxycorticosterone-producing tumor

414. Cortisol-producing adenoma

415. Aldosterone-producing adenoma

416. Androgen-producing adrenal tumor

417. Adrenal myelolipoma (functional rare)

418. Adrenal hemorrhage (endocrine failure)

419. Adrenal infarction (pregnancy; APS)

420. Congenital adrenal hypoplasia (NR0B1/DAX1)

421. Hyperinsulinism-hyperammonemia syndrome

422. Exercise-induced hyperinsulinism (SLC16A1)

423. Glucagon deficiency (post-pancreatectomy)

424. Somatostatin excess (somatostatinoma)

425. VIP excess (WDHA syndrome)

426. PPoma (pancreatic polypeptide excess)

427. Nesidioblastosis-related hypoglycemia (adult)

428. Autoimmune insulin syndrome (Hirata disease)

429. Anti-insulin receptor antibody syndrome

430. Insulin autoimmune syndrome (drug-induced)

431. Hyperthyrotropinemia (neonatal TSH surge abnormal)

432. Transient neonatal hyperthyroidism (maternal TRAb)

433. Transient neonatal hypothyroidism (maternal ATD)

434. Congenital goitrous hypothyroidism

435. Maternal hypothyroxinemia (fetal risk)

436. Isolated maternal hypothyroxinemia

437. Thyroid dyshormonogenesis (general)

438. TSH resistance syndrome

439. Thyroid-binding globulin excess

440. Thyroid-binding globulin deficiency

441. Primary hypergonadism (chemotherapy-induced)

442. Primary hypergonadism (radiation-induced)

443. Functional ovarian cyst–related estrogen excess

444. Hyperprolactinemia of pregnancy (physiologic exaggerated)

445. Galactocele (endocrine lactation issue)

446. Hyperrelaxin states (pregnancy)

447. Hyperplacentosis (hCG-mediated endocrine effects)

448. Hypersomatotropism (ectopic GHRH tumor)

449. Ectopic GHRH-secreting tumor

450. Carney triad endocrine components

451. Insulin resistance due to lipodystrophy

452. Familial partial lipodystrophy (Dunnigan)

453. Congenital generalized lipodystrophy (AGPAT2)

454. Congenital generalized lipodystrophy (BSCL2)

455. LMNA-related lipodystrophy

456. PPARG-related lipodystrophy

457. AKT2-related severe insulin resistance

458. INSR gene mutation (Donohue syndrome)

459. Rabson–Mendenhall syndrome

460. Short-stature homeobox (SHOX) deficiency (endocrine growth)

461. Hypercalciuria (endocrine causes)

462. Hypocalciuria (FHH)

463. Hyperoxaluria-related bone disease (endocrine)

464. Hyperparathyroid bone cysts (brown tumors)

465. Osteitis fibrosa cystica

466. Adynamic bone disease (endocrine/renal)

467. Osteoporosis in hyperthyroidism

468. Osteoporosis in Cushing syndrome

469. Osteoporosis in hypogonadism

470. Osteoporosis in diabetes

471. MEN1-related insulinoma

472. MEN1-related gastrinoma

473. MEN1-related prolactinoma

474. MEN1-related nonfunctioning pituitary adenoma

475. Carney complex—PPNAD (Cushing)

476. Carney complex—thyroid lesions

477. Carney complex—testicular tumors (LCCSCT)

478. McCune-Albright—precocious puberty

479. McCune-Albright—thyrotoxicosis

480. McCune-Albright—GH excess

481. Hypogonadism in chronic systemic disease (endocrine)

482. Thyroid dysfunction in chronic kidney disease

483. Thyroid dysfunction in liver disease

484. Adrenal insufficiency in critical illness

485. Relative adrenal insufficiency (CIRCI)

486. Sick-euthyroid syndrome (nonthyroidal illness)

487. Hypothalamic–pituitary–adrenal axis suppression (steroids)

488. Opioid-induced adrenal insufficiency

489. Opioid-induced hypogonadism

490. Antipsychotic-induced hyperprolactinemia

491. Hyperthyroidism due to hCG (gestational)

492. Trophoblastic tumor–induced thyrotoxicosis

493. Struma ovarii (thyrotoxicosis)

494. Thyrotropin resistance (familial)

495. Pituitary TSH deficiency (central hypothyroidism)

496. Central hyperthyroidism (TSHoma)

497. Resistance to IGF-1

498. GH-secreting ectopic tumor (rare)

499. Ectopic calcitonin syndrome (rare)

500. Paraneoplastic SIADH (endocrine)

501. Post-thyroidectomy hypocalcemia

502. Hungry bone after parathyroidectomy

503. Post-adrenalectomy adrenal insufficiency

504. Post-hypophysectomy hypopituitarism

505. Post-radioiodine hypothyroidism

506. Post-bariatric endocrine deficiencies

507. Post-transplant hypophosphatemia (FGF23)

508. Refeeding hypophosphatemia (endocrine)

509. Refeeding hypokalemia (endocrine)

510. Refeeding hypomagnesemia (endocrine)

511. Hyperthyroidism due to thyroid hormone overuse

512. Hypothyroidism due to poor adherence

513. Factitious Cushing syndrome (exogenous steroids)

514. Factitious hyperinsulinism

515. Factitious SIADH (excess water intake)

516. Iatrogenic hypopituitarism (radiation)

517. Iatrogenic hypogonadism (GnRH analogs)

518. Iatrogenic hyperprolactinemia (metoclopramide)

519. Iatrogenic diabetes insipidus (lithium)

520. Iatrogenic hypercalcemia (vitamin D)

521. Hyperthyroidism in neonates (maternal TRAb)

522. Hypothyroidism in neonates (congenital)

523. Neonatal hypocalcemia (transient)

524. Neonatal hypercalcemia (Williams syndrome)

525. Neonatal adrenal insufficiency (STAR)

526. Neonatal hypopituitarism

527. Neonatal hypoglycemia (endocrine)

528. Neonatal hyperinsulinism (KATP)

529. Neonatal SIADH

530. Neonatal DI (central)

531. Glucocorticoid-remediable aldosteronism (FH-I)

532. Familial hyperaldosteronism type III (KCNJ5)

533. Familial hyperaldosteronism type IV (CACNA1H)

534. Liddle syndrome (ENaC gain-of-function)

535. Mineralocorticoid receptor activating mutation

536. 11β-HSD2 deficiency (AME)

537. Licorice-induced pseudohyperaldosteronism

538. Renin-secreting tumor (juxtaglomerular)

539. Renin deficiency (hypoaldosteronism)

540. Hyperreninemic hyperaldosteronism (secondary)

541. Thyroid hormone excess in athletes (misuse)

542. Anabolic steroid–induced hypogonadism

543. Antiandrogen therapy–induced endocrine effects

544. GnRH agonist therapy–related hypogonadism

545. SERM-related endocrine effects

546. Aromatase inhibitor–related endocrine effects

547. Amiodarone thyroid dysfunction (general)

548. Interferon-induced thyroiditis

549. Tyrosine kinase inhibitor–induced hypothyroidism

550. Immune checkpoint inhibitor–hypophysitis

551. Primary hyperoxaluria endocrine bone effects

552. Wilson disease endocrine effects

553. Glycogen storage disease endocrine effects

554. Mitochondrial diabetes (MIDD)

555. Wolfram syndrome (DIDMOAD)

556. Thiamine-responsive megaloblastic anemia with diabetes

557. HNF1B nephropathy with diabetes

558. RCAD syndrome (renal cysts and diabetes, HNF1B)

559. Maternally inherited diabetes and deafness (MIDD)

560. NAFLD-related endocrine disturbances

561. Primary thyroid amyloidosis

562. Systemic amyloidosis with endocrine involvement

563. Amyloid infiltration of pituitary

564. Amyloid infiltration of adrenals

565. Amyloid infiltration of pancreas (islets; T2D)

566. Hemochromatosis thyroid dysfunction

567. Hemochromatosis hypogonadism (pituitary)

568. Sarcoidosis thyroid dysfunction

569. Sarcoidosis pituitary involvement

570. Sarcoidosis adrenal involvement

571. Endocrine hypertension (primary aldosteronism)

572. Endocrine hypertension (pheochromocytoma)

573. Endocrine hypertension (Cushing)

574. Endocrine hypertension (thyrotoxicosis)

575. Endocrine hypotension (adrenal insufficiency)

576. Orthostatic intolerance (adrenal/AN)

577. Hyperkalemia due to hypoaldosteronism

578. Hypokalemia due to hyperaldosteronism

579. Hypernatremia due to DI

580. Hyponatremia due to SIADH

581. Menopause (endocrine deficiency state)

582. Premature menopause (POI)

583. Andropause (late-onset hypogonadism)

584. HRT-related endocrine effects (women)

585. TRT-related endocrine effects (men)

586. Contraceptive-related endocrine effects

587. Hyperprogestinism (exogenous)

588. Estrogen excess (exogenous)

589. Anti-estrogen effects (endocrine)

590. GnRH antagonist–related effects

591. Thyroid dysfunction in Down syndrome

592. Thyroid dysfunction in Turner syndrome

593. Thyroid dysfunction in Williams syndrome

594. Thyroid dysfunction in Prader–Willi syndrome

595. Adrenal dysfunction in APS type 1

596. Autoimmune polyendocrine syndrome type 1

597. Autoimmune polyendocrine syndrome type 2

598. IPEX syndrome (endocrine autoimmunity)

599. APS with AIRE mutation (type 1)

600. POEMS syndrome (endocrine components)

601. Hyperparathyroidism in MEN1

602. Insulinoma in MEN1

603. Gastrinoma in MEN1

604. Prolactinoma in MEN1

605. Medullary thyroid carcinoma in MEN2

606. Pheochromocytoma in MEN2

607. Primary hyperparathyroidism in MEN2

608. Pituitary tumors in MEN4 (CDKN1B)

609. PPGL syndromes (SDHx)

610. Hereditary paraganglioma–pheochromocytoma syndromes

611. Primary thyroid failure after radioiodine

612. Primary thyroid failure after thyroidectomy

613. Subclinical hypothyroidism (elderly)

614. Subclinical hyperthyroidism (elderly)

615. Hyperthyroidism due to thyroiditis (transient)

616. Hypothyroidism due to thyroiditis (transient)

617. T3 thyrotoxicosis

618. T4 thyrotoxicosis

619. Thyrotoxicosis with negative uptake (thyroiditis)

620. Thyrotoxicosis with positive uptake (Graves/toxic nodule)

621. Central adrenal insufficiency (pituitary)

622. Tertiary adrenal insufficiency (hypothalamic)

623. ACTH deficiency (isolated)

624. CRH deficiency (rare)

625. Glucocorticoid hypersensitivity (rare)

626. Mineralocorticoid hypersensitivity (rare)

627. Adrenal androgen insufficiency

628. DHEA-S deficiency (aging)

629. Primary cortisol deficiency (familial)

630. Familial glucocorticoid deficiency

631. Thyroid carcinoma—familial non-medullary

632. Thyroid carcinoma—radiation exposure childhood

633. Thyroid microcarcinoma multifocal

634. Tall cell variant papillary thyroid cancer

635. Diffuse sclerosing variant papillary thyroid cancer

636. Follicular carcinoma minimally invasive

637. Follicular carcinoma widely invasive

638. Hürthle cell carcinoma minimally invasive

639. Medullary thyroid carcinoma—sporadic

640. Medullary thyroid carcinoma—familial

641. Endocrine causes of infertility (women)

642. Endocrine causes of infertility (men)

643. Hyperprolactinemic infertility

644. Thyroid-related infertility

645. PCOS-related infertility

646. Hypogonadism-related infertility

647. Congenital adrenal hyperplasia–related infertility

648. Luteal insufficiency infertility

649. Endocrine recurrent pregnancy loss

650. Endocrine erectile dysfunction

651. Hypercalcemia secondary to hyperthyroidism

652. Hypercalcemia secondary to adrenal insufficiency

653. Hypocalcemia in pancreatitis (endocrine ties)

654. Hypocalcemia in sepsis (endocrine ties)

655. Hyperphosphatemia in hypoparathyroidism

656. Hypophosphatemia in hyperparathyroidism

657. FGF23-mediated hypophosphatemia (XLH)

658. FGF23-mediated oncogenic osteomalacia

659. Calcitonin-secreting tumors (MTC)

660. PTHrP-mediated hypercalcemia

661. Thyroid storm (severe thyrotoxicosis)

662. Myxedema coma (severe hypothyroidism)

663. Adrenal crisis (acute AI)

664. Pituitary apoplexy (endocrine emergency)

665. Hypercalcemic crisis (primary HPT)

666. Hypocalcemic tetany (acute)

667. Severe hyponatremia due to SIADH

668. Severe hypernatremia due to DI

669. DKA (diabetic emergency)

670. HHS (diabetic emergency)

671. Endocrine orbitopathy (Graves)

672. Endocrine dermopathy (pretibial myxedema)

673. Endocrine cardiomyopathy (thyrotoxic)

674. Endocrine myopathy (Cushing)

675. Endocrine myopathy (hypothyroid)

676. Endocrine neuropathy (diabetic autonomic)

677. Endocrine neuropathy (nutritional/endocrine)

678. Endocrine arthropathy (diabetic cheiroarthropathy)

679. Endocrine hepatopathy (NAFLD in T2D)

680. Endocrine nephropathy (diabetic)

681. Post-COVID endocrine dysfunction (thyroid)

682. Post-COVID endocrine dysfunction (adrenal)

683. Post-COVID endocrine dysfunction (gonadal)

684. Post-COVID dysglycemia

685. Vaccine-associated thyroiditis (rare)

686. Vaccine-associated adrenal events (rare)

687. Long-COVID dysautonomia with endocrine overlap

688. Post-viral hypophysitis (rare)

689. Post-infectious thyroiditis (general)

690. Post-infectious SIADH

691. Thyroid hormone over-replacement cardiotoxicity

692. T3-only therapy complications

693. Desiccated thyroid overuse effects

694. Over-replacement glucocorticoid complications

695. Over-replacement mineralocorticoid complications

696. Over-replacement growth hormone complications

697. Over-replacement sex steroid complications

698. Bisphosphonate-related endocrine considerations

699. SGLT2-related euglycemic DKA (endocrine)

700. GLP-1RA-related endocrine effects

701. Hyperinsulinemic acanthosis nigricans

702. Hyperandrogenic acne (endocrine)

703. Hidradenitis with endocrine overlap (androgens)

704. Hirsutism (PCOS)

705. Female pattern hair loss (endocrine)

706. Male pattern hair loss (androgen-related)

707. Virilization from exogenous androgens

708. Feminization from estrogen-secreting tumor

709. Galactorrhea (non-pregnant)

710. Gynecomastia (physiologic)

711. Thyroid disease in elderly (frailty)

712. Adrenal insufficiency in elderly

713. Osteoporosis in elderly men

714. Osteoporosis in elderly women

715. Hypogonadism of aging (men)

716. Menopausal vasomotor symptoms (endocrine)

717. Parathyroid disease in elderly

718. SIADH in elderly

719. DI in elderly

720. Hypothyroidism in elderly (subtle)

721. Endocrine causes of hypertension (general)

722. Endocrine causes of hypotension (general)

723. Endocrine causes of hyperkalemia

724. Endocrine causes of hypokalemia

725. Endocrine causes of hyponatremia

726. Endocrine causes of hypernatremia

727. Endocrine causes of hypercalcemia

728. Endocrine causes of hypocalcemia

729. Endocrine causes of hypophosphatemia

730. Endocrine causes of hyperphosphatemia

731. Thyroid hormone resistance (beta)

732. Thyroid hormone resistance (alpha)

733. Generalized thyroid hormone resistance

734. Pituitary thyroid hormone resistance

735. Selective pituitary resistance to thyroid hormone

736. Selective peripheral resistance to thyroid hormone

737. TSH receptor–mediated hyperthyroidism (familial)

738. TSH receptor–mediated hypothyroidism (familial)

739. GNAS-related hyperthyroidism (McCune–Albright)

740. PDE11A-related adrenal hyperplasia

741. Endocrine tumor syndrome (MEN variants)

742. Hypercortisolism due to alcoholism (pseudo-Cushing)

743. Hypercortisolism due to depression (pseudo-Cushing)

744. Hypercortisolism due to obesity (pseudo-Cushing)

745. Hypercortisolism due to PCOS (pseudo-Cushing)

746. Subclinical hypercortisolism (adrenal incidentaloma)

747. Mild autonomous cortisol secretion (MACS)

748. Low-renin hypertension (endocrine)

749. High-renin hypertension (endocrine)

750. Resistant hypertension (endocrine evaluation)

751. Hypothyroidism after immune therapy

752. Hyperthyroidism after immune therapy

753. Hypophysitis after immune therapy

754. Adrenalitis after immune therapy

755. Diabetes after immune therapy

756. Hypogonadism after chemotherapy

757. Hyperprolactinemia after psychotropics

758. SIADH after SSRIs

759. DI after lithium

760. Hypercalcemia after thiazides

761. Brown-Vialetto–Van Laere with endocrine overlap

762. Ataxia-telangiectasia endocrine effects

763. Myotonic dystrophy endocrine effects

764. Friedreich ataxia endocrine effects

765. Spinal muscular atrophy endocrine effects

766. Dystrophinopathy endocrine effects

767. 21-hydroxylase inhibitor exposure effects

768. 5-alpha-reductase inhibitor endocrine effects

769. Anti-aromatase exposure in youth (endocrine)

770. Exogenous hCG misuse (thyroid/androgen effects)

771. Endocrine aspects of anorexia nervosa

772. Endocrine aspects of bulimia nervosa

773. Endocrine aspects of binge-eating disorder

774. Female athlete triad (endocrine)

775. Relative energy deficiency in sport (RED-S)

776. Osteoporosis of eating disorders

777. Hypogonadism in chronic illness

778. Hypothyroidism in chronic illness

779. Adrenal suppression in chronic opioid therapy

780. Hyperprolactinemia in stress

781. Hyperinsulinemic polycystic ovary syndrome

782. Non-hyperinsulinemic PCOS variant

783. Normoandrogenic PCOS

784. Hyperandrogenic PCOS

785. PCOS with metabolic syndrome

786. Lean PCOS

787. Obese PCOS

788. PCOS with infertility

789. PCOS with hirsutism

790. PCOS with insulin resistance

791. Endocrine sarcopenia (hypogonadism)

792. Endocrine sarcopenia (hyperthyroidism)

793. Endocrine sarcopenia (Cushing)

794. Endocrine cachexia (hyperthyroid)

795. Endocrine edema (hypothyroid)

796. Endocrine hypertension (hyperthyroid)

797. Endocrine hypotension (adrenal)

798. Endocrine tachycardia (thyrotoxic)

799. Endocrine bradycardia (hypothyroid)

800. Endocrine dyslipidemia (hypothyroid)

801. Hyperthyroidism in subacute thyroiditis

802. Hypothyroidism after subacute thyroiditis

803. Hyperthyroidism in painless thyroiditis

804. Hypothyroidism after painless thyroiditis

805. Hyperthyroidism in postpartum thyroiditis

806. Hypothyroidism after postpartum thyroiditis

807. Recurrent thyroiditis

808. Chronic autoimmune thyroiditis (Hashimoto)

809. Atrophic thyroiditis (autoimmune)

810. Fibrosing (Riedel) thyroiditis

811. Euthyroid Graves ophthalmopathy

812. Isolated T3 toxicosis

813. Thyroxine-binding globulin excess

814. Thyroxine-binding globulin deficiency

815. Familial dysalbuminemic hyperthyroxinemia

816. High TBG in pregnancy (physiologic disorder context)

817. Low TBG in liver disease (endocrine)

818. Pituitary resistance to thyroid hormone

819. Assay interference causing thyroid dysfunction (HAMA)

820. Biotin interference mimicking thyroid disease

821. Adrenal hypoplasia congenita (DAX1)

822. Triple A syndrome (Allgrove)

823. Smith–Lemli–Opitz endocrine aspects

824. Laurence–Moon–Biedl endocrine aspects

825. APECED (APS-1) classic triad

826. APS-2 (Schmidt syndrome)

827. APS-3 (thyroiditis with other autoimmunity)

828. APS-4 (other combinations)

829. Iodine deficiency disorders (IDD)

830. Endemic cretinism (historical)

831. Hyperthyroidism due to toxic multinodular goiter

832. Hyperthyroidism due to toxic adenoma

833. Hypothyroidism due to thyroid agenesis

834. Hypothyroidism due to ectopic thyroid

835. Hypothyroidism due to hemiagenesis

836. Hypothyroidism due to thyroid hemi-hypoplasia

837. Dyshormonogenesis—TPO defect

838. Dyshormonogenesis—thyroglobulin defect

839. Dyshormonogenesis—pendrin defect

840. Dyshormonogenesis—DUOX2 defect

841. Hyperprolactinemia due to stalk effect

842. Hyperprolactinemia due to chest wall lesion

843. Hyperprolactinemia due to hypothyroidism

844. Hyperprolactinemia due to renal failure

845. Hyperprolactinemia due to cirrhosis

846. Hyperprolactinemia idiopathic

847. Macroprolactinemia

848. Prolactin-secreting microadenoma

849. Prolactin-secreting macroadenoma

850. Drug-resistant prolactinoma

851. Primary amenorrhea—endocrine causes

852. Secondary amenorrhea—endocrine causes

853. Oligomenorrhea—endocrine causes

854. Dysmenorrhea—endocrine overlap (endometriosis hormones)

855. Abnormal uterine bleeding—endocrine (anovulatory)

856. Hyperestrogenism—obesity-related

857. Hypoestrogenism—athletic amenorrhea

858. Androgen excess—PCOS

859. Androgen excess—CAH

860. Androgen excess—tumoral

861. Hypoglycemia due to insulin autoimmune syndrome

862. Hypoglycemia due to IGF-2–secreting tumor

863. Hypoglycemia due to adrenal insufficiency

864. Hypoglycemia due to hypopituitarism

865. Hypoglycemia due to alcohol

866. Hypoglycemia due to critical illness

867. Hypoglycemia due to gastric surgery

868. Hypoglycemia due to liver failure

869. Hypoglycemia due to renal failure

870. Hypoglycemia due to reactive postprandial causes

871. Hyperthyroidism with atrial fibrillation

872. Hyperthyroidism with osteoporosis

873. Hypothyroidism with hyperlipidemia

874. Hypothyroidism with pericardial effusion

875. Cushing syndrome with diabetes

876. Cushing syndrome with osteoporosis

877. Acromegaly with sleep apnea

878. Acromegaly with cardiomyopathy

879. Hyperaldosteronism with resistant hypertension

880. Pheochromocytoma with cardiomyopathy

881. Thyroid hormone misuse for weight loss

882. DNP misuse endocrine consequences

883. Growth hormone misuse (athletics)

884. Anabolic steroid misuse (endocrine)

885. hCG misuse (weight loss)

886. Insulin misuse (bodybuilding)

887. Thyroid extract misuse

888. Over-the-counter supplement thyroid effects

889. Herbal-induced thyroid dysfunction

890. Biotin-induced lab artifact endocrine issues

891. Endocrine aging of bone (osteopenia)

892. Endocrine aging of muscle (sarcopenia)

893. Endocrine aging of adipose (redistribution)

894. Endocrine aging of pancreas (β-cell decline)

895. Endocrine aging of gonads (testosterone decline)

896. Endocrine aging of ovaries (menopause)

897. Endocrine aging of pituitary (GH decline)

898. Endocrine aging of thyroid (TSH drift)

899. Endocrine aging of adrenals (DHEA decline)

900. Endocrine aging of calcium metabolism (PTH rise)

901. Thyroid hormone resistance due to THRB mutation

902. Thyroid hormone resistance due to THRA mutation

903. Pseudohyperthyroidism (assay interference)

904. Pseudohypothyroidism (assay interference)

905. Familial dysalbuminemic hyperthyroxinemia

906. Transthyretin variants causing T4 binding changes

907. TBG excess—X-linked

908. TBG deficiency—X-linked

909. Albumin variants—thyroid test artifacts

910. Heterophile antibodies—pituitary hormone assay errors

911. Hyperaldosteronism—sleep apnea association

912. Thyroid dysfunction—lithium association

913. Thyroid dysfunction—amiodarone association

914. Thyroid dysfunction—iodinated contrast exposure

915. Thyroid dysfunction—interferon therapy

916. Thyroid dysfunction—TKI therapy

917. Thyroid dysfunction—checkpoint inhibitors

918. Thyroid dysfunction—antiepileptics

919. Thyroid dysfunction—rifampin

920. Thyroid dysfunction—sunitinib

921. Endocrine aspects of osteoporosis in men

922. Endocrine aspects of fragility fractures

923. Hyperparathyroid bone disease in CKD

924. Osteoporosis in primary hyperparathyroidism

925. Osteoporosis in hypogonadism (men)

926. Osteoporosis in POI (women)

927. Osteoporosis in Cushing’s

928. Osteoporosis in hyperthyroidism

929. Osteoporosis in T1D

930. Osteoporosis in T2D

931. Hyperinsulinemia in obesity

932. Leptin resistance in obesity

933. Adiponectin deficiency in metabolic syndrome

934. Ghrelin excess in Prader–Willi

935. Ghrelin deficiency after bariatric surgery

936. Incretin deficiency post-gastrectomy

937. GLP-1 resistance hypotheses

938. DPP-4 hyperactivity (metabolic)

939. FGF21 resistance (obesity)

940. FGF19-related bile acid endocrine effects

941. Thyroid carcinoma—pediatric

942. Thyroid carcinoma—familial syndromes

943. Adrenocortical carcinoma—pediatric

944. Pheochromocytoma—pediatric

945. Pituitary adenoma—pediatric

946. Craniopharyngioma—pediatric endocrine sequelae

947. CAH—classical salt-wasting

948. CAH—simple virilizing

949. CAH—non-classical

950. Hypoglycemia of infancy (transient)

951. Hypothalamic amenorrhea—stress related

952. Hypothalamic amenorrhea—weight loss

953. Hypothalamic amenorrhea—exercise

954. Hyperprolactinemia—microadenoma

955. Hyperprolactinemia—macroadenoma

956. Hyperprolactinemia—idiopathic

957. Galactorrhea—idiopathic

958. Hyperandrogenism—idiopathic hirsutism

959. PCOS—adolescent phenotype

960. PCOS—postmenopausal persistence

961. Thyroid nodule—autonomous functioning

962. Thyroid nodule—colloid

963. Thyroid nodule—thyroiditis related

964. Thyroid nodule—Hürthle cell adenoma

965. Thyroid nodule—follicular adenoma

966. Thyroid nodule—cystic

967. Thyroid nodule—spongiform

968. Thyroid nodule—radiation-related

969. Thyroid nodule—iodine deficiency related

970. Thyroid nodule—multifocal

971. Hypoparathyroidism—autoimmune (APS)

972. Hypoparathyroidism—genetic (GCM2)

973. Hypoparathyroidism—DiGeorge (22q11.2)

974. Hypoparathyroidism—HDR syndrome (GATA3)

975. Hypoparathyroidism—CaSR activating mutations

976. Hypoparathyroidism—postsurgical permanent

977. Hypoparathyroidism—postsurgical transient

978. Pseudohypoparathyroidism—Albright osteodystrophy

979. Pseudopseudohypoparathyroidism—AHO phenotype

980. Normocalcemic primary hyperparathyroidism (repeat distinct)

981. Central hypothyroidism—pituitary tumor

982. Central hypothyroidism—radiation

983. Central hypothyroidism—trauma

984. Central hypothyroidism—infiltrative disease

985. Central hypothyroidism—congenital

986. Central DI—autoimmune

987. Central DI—traumatic

988. Central DI—post-surgical

989. Nephrogenic DI—genetic (AVPR2)

990. Nephrogenic DI—acquired (lithium)

991. SIADH—CNS disorder related

992. SIADH—pulmonary disorder related

993. SIADH—drug induced (SSRIs)

994. SIADH—paraneoplastic

995. Reset osmostat variant of SIADH

996. Pregnancy-related DI (vasopressinase)

997. Primary polydipsia—psychogenic

998. Dipsogenic DI (thirst center lesion)

999. Gestational thyrotoxicosis (hCG-mediated)

1000. Hyperthyroidism due to molar pregnancy

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 30, 2025.

PDF Documents For This Disease Condition References